Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ExPEC9V vaccine phase 3 prevention study in older adults at risk for invasive E. coli disease
2023-506589-30-00Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jun 2024
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 20
01
Overview
Phase 3, randomised, double-blind trial in invasive extraintestinal pathogenic Escherichia coli disease (IED) comparing ExPEC9V vaccine with Placebo (2 arms). Started Jun 2024; status: completed.
02
Drugs
ExPEC9V
03
Conditions
invasive extraintestinal pathogenic Escherichia coli disease (IED)
Beyond the preview
Go deeper on 2023-506589-30-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506589-30-00.